Faruqi & Faruqi, LLP Announces the Investigation of Dyax Corp. (DYAX) Over the Proposed Sale of the Company to Shire plc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Dyax Corp. (“Dyax” or the “Company”) (NasdaqGM:DYAX) for potential breaches of fiduciary duties in connection with the sale of the Company to Shire plc. for approximately $5.4 billion.
The Company’s stockholders will only receive $37.30 in cash (plus $4.00 in cash per share upon clinical approval of DX-2930) for each share of Dyax common stock they own. However, the offer seems inadequate since Shire plc. expects approximately $2.0 billion in annual sales from DX-2930 if approved.
If you own common stock in Dyax and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Juan Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.